<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--  EDGAR Online I-Metrix Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!--  Version: 6.0.7 -->
<!--  Creation date: 2009-07-29T06:24Z -->
<!--  Copyright (c) 2005-2009 EDGAR Online, Inc. All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.us/dei/2008-03-31" xmlns:teva="http://www.tevapharm.com/20090630" xmlns:us-gaap="http://xbrl.us/us-gaap/2008-03-31" xmlns:us-roles="http://xbrl.us/us-roles/2008-03-31" xmlns:us-types="http://xbrl.us/us-types/2008-03-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="teva-20090630.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <dei:EntityPublicFloat contextRef="eol_PE3710----096-K-0007_STD_Inst_20080630_0" unitRef="USD" decimals="0">38814968445</dei:EntityPublicFloat>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE3710----096-K-0007_STD_Inst_20080630_0" unitRef="USD" decimals="-6">2484000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="Shares" decimals="0">911897295</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:Assets contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">32251000000</us-gaap:Assets>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="Shares" decimals="-6">1500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="Shares" decimals="-6">912000000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="Shares" decimals="-6">912000000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">49000000</us-gaap:CommonStockValue>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">290000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">1602000000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:AccountsPayable contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">2129000000</us-gaap:AccountsPayable>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">12498000000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">4376000000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">11035000000</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">1761000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">861000000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:DebtCurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">2028000000</us-gaap:DebtCurrent>
  <us-gaap:Goodwill contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">12218000000</us-gaap:Goodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">4349000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:InventoryNet contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">3496000000</us-gaap:InventoryNet>
  <us-gaap:Liabilities contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">14401000000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">32251000000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">7240000000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesNoncurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">7161000000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LongTermInvestmentsAndReceivablesNet contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">459000000</us-gaap:LongTermInvestmentsAndReceivablesNet>
  <us-gaap:MinorityInterest contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">35000000</us-gaap:MinorityInterest>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">464000000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">623000000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">1360000000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">3726000000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">5902000000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">3857000000</us-gaap:SeniorLongTermNotes>
  <us-gaap:ShortTermInvestments contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">42000000</us-gaap:ShortTermInvestments>
  <us-gaap:StockholdersEquity contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">17815000000</us-gaap:StockholdersEquity>
  <us-gaap:TreasuryStockShares contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="Shares" decimals="-6">38000000</us-gaap:TreasuryStockShares>
  <us-gaap:TreasuryStockValue contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">924000000</us-gaap:TreasuryStockValue>
  <teva:EmployeeRelatedLiabilitiesNoncurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">186000000</teva:EmployeeRelatedLiabilitiesNoncurrent>
  <teva:SalesReservesAllowances contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">2460000000</teva:SalesReservesAllowances>
  <teva:OtherPayables contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">655000000</teva:OtherPayables>
  <teva:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE3710----096-K-0007_STD_Inst_20090630_0" unitRef="USD" decimals="-6">17850000000</teva:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE3710----096-K-0007_STD_Inst_20071231_0" unitRef="USD" decimals="-6">1488000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:Assets contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">32920000000</us-gaap:Assets>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="Shares" decimals="-6">1500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="Shares" decimals="-6">889000000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="Shares" decimals="-6">889000000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">48000000</us-gaap:CommonStockValue>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">390000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">1723000000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:AccountsPayable contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">2244000000</us-gaap:AccountsPayable>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6" id="fnid_395223_2_34">11673000000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">4653000000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">11426000000</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">1854000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6" id="fnid_395223_2_26">1821000000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:DebtCurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">2906000000</us-gaap:DebtCurrent>
  <us-gaap:Goodwill contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">12297000000</us-gaap:Goodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">4581000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:InventoryNet contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">3396000000</us-gaap:InventoryNet>
  <us-gaap:Liabilities contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">16482000000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">32920000000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">8481000000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesNoncurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">8001000000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LongTermInvestmentsAndReceivablesNet contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">425000000</us-gaap:LongTermInvestmentsAndReceivablesNet>
  <us-gaap:MinorityInterest contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">60000000</us-gaap:MinorityInterest>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6" id="fnid_395223_2_12">492000000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">623000000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">1470000000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">3699000000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6" id="fnid_395223_2_35">5191000000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">3654000000</us-gaap:SeniorLongTermNotes>
  <us-gaap:ShortTermInvestments contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">53000000</us-gaap:ShortTermInvestments>
  <us-gaap:StockholdersEquity contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">16378000000</us-gaap:StockholdersEquity>
  <us-gaap:TreasuryStockShares contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="Shares" decimals="-6">38000000</us-gaap:TreasuryStockShares>
  <us-gaap:TreasuryStockValue contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">924000000</us-gaap:TreasuryStockValue>
  <teva:EmployeeRelatedLiabilitiesNoncurrent contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">182000000</teva:EmployeeRelatedLiabilitiesNoncurrent>
  <teva:SalesReservesAllowances contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">2708000000</teva:SalesReservesAllowances>
  <teva:OtherPayables contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">621000000</teva:OtherPayables>
  <teva:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE3710----096-K-0007_STD_Inst_20081231_0" unitRef="USD" decimals="-6">16438000000</teva:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="USDperShareItemType" decimals="2">0.68</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="USDperShareItemType" decimals="2">0.65</us-gaap:EarningsPerShareDiluted>
  <us-gaap:CostOfGoodsAndServicesSold contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="USD" decimals="-6">1318000000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="USD" decimals="-6">169000000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GrossProfit contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="USD" decimals="-6">1505000000</us-gaap:GrossProfit>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="USD" decimals="-6">604000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="USD" decimals="-6">-1000000</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="USD" decimals="-6" id="fnid_395221_2_11">68000000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="USD" decimals="-6">533000000</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="USD" decimals="-6" id="fnid_395221_2_9">-34000000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="USD" decimals="-6">638000000</us-gaap:OperatingIncomeLoss>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="USD" decimals="-6">198000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="USD" decimals="-6">0</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="USD" decimals="-6">0</us-gaap:RestructuringSettlementAndImpairmentProvisions>
  <us-gaap:SalesRevenueNet contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="USD" decimals="-6">2823000000</us-gaap:SalesRevenueNet>
  <us-gaap:SellingAndMarketingExpense contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="USD" decimals="-6">500000000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="Shares" decimals="-6">836000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="Shares" decimals="-6">778000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <teva:IncomeBeforeMinorityInterestEarningsLossEquityInvestments contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="USD" decimals="-6">536000000</teva:IncomeBeforeMinorityInterestEarningsLossEquityInvestments>
  <teva:ProfitLoss contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="USD" decimals="-6">535000000</teva:ProfitLoss>
  <teva:NetIncomeLossAttributableToNoncontrollingInterest contextRef="eol_PE3710----096-K-0007_STD_p3m_20080630_0" unitRef="USD" decimals="-6">2000000</teva:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="USDperShareItemType" decimals="2">0.61</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="USDperShareItemType" decimals="2">0.58</us-gaap:EarningsPerShareDiluted>
  <us-gaap:CostOfGoodsAndServicesSold contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="USD" decimals="-6">1631000000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="USD" decimals="-6">197000000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GrossProfit contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="USD" decimals="-6">1769000000</us-gaap:GrossProfit>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="USD" decimals="-6">641000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="USD" decimals="-6">-20000000</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="USD" decimals="-6">98000000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="USD" decimals="-6">521000000</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="USD" decimals="-6">-61000000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="USD" decimals="-6">702000000</us-gaap:OperatingIncomeLoss>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="USD" decimals="-6">169000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="USD" decimals="-6">0</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="USD" decimals="-6">52000000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
  <us-gaap:SalesRevenueNet contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="USD" decimals="-6">3400000000</us-gaap:SalesRevenueNet>
  <us-gaap:SellingAndMarketingExpense contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="USD" decimals="-6">649000000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="Shares" decimals="-6">895000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="Shares" decimals="-6">860000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <teva:IncomeBeforeMinorityInterestEarningsLossEquityInvestments contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="USD" decimals="-6">543000000</teva:IncomeBeforeMinorityInterestEarningsLossEquityInvestments>
  <teva:ProfitLoss contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="USD" decimals="-6">523000000</teva:ProfitLoss>
  <teva:NetIncomeLossAttributableToNoncontrollingInterest contextRef="eol_PE3710----096-K-0007_STD_p3m_20090630_0" unitRef="USD" decimals="-6">2000000</teva:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">996000000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USDperShareItemType" decimals="2">0.86</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USDperShareItemType" decimals="2">0.82</us-gaap:EarningsPerShareDiluted>
  <us-gaap:AssetImpairmentCharges contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">82000000</us-gaap:AssetImpairmentCharges>
  <us-gaap:CostOfGoodsAndServicesSold contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">2518000000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6" id="fnid_395222_2_4">-154000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">246000000</us-gaap:DepreciationAndAmortization>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">92000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">12000000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">331000000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GrossProfit contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">2877000000</us-gaap:GrossProfit>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">835000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6" id="fnid_395221_4_13">0</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6" id="fnid_395221_4_11">160000000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInOperatingCapital contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">-232000000</us-gaap:IncreaseDecreaseInOperatingCapital>
  <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6" id="fnid_395222_2_9">-63000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">-521000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">-127000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">1552000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6" id="fnid_395221_4_16">672000000</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6" id="fnid_395221_4_9">-100000000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">935000000</us-gaap:OperatingIncomeLoss>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">-72000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsOfDividends contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">201000000</us-gaap:PaymentsOfDividends>
  <us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">414000000</us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">1353000000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">322000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromRepaymentsOfShortTermDebt contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">-128000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">3000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">1890000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">45000000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:RepaymentsOfConvertibleDebt contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">141000000</us-gaap:RepaymentsOfConvertibleDebt>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">111000000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:RepaymentsOfOtherDebt contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">0</us-gaap:RepaymentsOfOtherDebt>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">377000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">382000000</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">0</us-gaap:RestructuringSettlementAndImpairmentProvisions>
  <us-gaap:SalesRevenueNet contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">5395000000</us-gaap:SalesRevenueNet>
  <us-gaap:SellingAndMarketingExpense contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">852000000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">29000000</us-gaap:ShareBasedCompensation>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="Shares" decimals="-6">820000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="Shares" decimals="-6">777000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <teva:IncomeBeforeMinorityInterestEarningsLossEquityInvestments contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">675000000</teva:IncomeBeforeMinorityInterestEarningsLossEquityInvestments>
  <teva:AdjustmentResearchAndDevelopmentInProcess contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">382000000</teva:AdjustmentResearchAndDevelopmentInProcess>
  <teva:ProfitLoss contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">675000000</teva:ProfitLoss>
  <teva:NetIncomeLossAttributableToNoncontrollingInterest contextRef="eol_PE3710----096-K-0007_STD_p6m_20080630_0" unitRef="USD" decimals="-6">3000000</teva:NetIncomeLossAttributableToNoncontrollingInterest>
  <dei:DocumentType contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">6-K</dei:DocumentType>
  <dei:AmendmentFlag contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">false</dei:AmendmentFlag>
  <dei:AmendmentDescription contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">N.A.</dei:AmendmentDescription>
  <dei:DocumentPeriodEndDate contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">2009-06-30</dei:DocumentPeriodEndDate>
  <dei:EntityRegistrantName contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">TEVA PHARMACEUTICAL INDUSTRIES LTD</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">0000818686</dei:EntityCentralIndexKey>
  <dei:TradingSymbol contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">TEVA</dei:TradingSymbol>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityWellKnownSeasonedIssuer contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">Yes</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityVoluntaryFilers contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">No</dei:EntityVoluntaryFilers>
  <dei:EntityCurrentReportingStatus contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">Large Accelerated Filer</dei:EntityFilerCategory>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">-93000000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USDperShareItemType" decimals="2">1.13</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USDperShareItemType" decimals="2">1.09</us-gaap:EarningsPerShareDiluted>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;NOTE 12 &amp;#8211;
Contingencies:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;i&gt;General&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;From time to time, Teva and
its subsidiaries are subject to legal claims for damages and/or
equitable relief arising in the ordinary course of business. In
addition, as described below, in large part as a result of the
nature of its business, Teva is frequently subject to patent
litigation. Teva believes it has meritorious defenses to the
actions to which it is a party and expects to pursue vigorously the
defense of each of the ongoing actions, including those described
below. Based upon the status of these cases, the advice of counsel,
management&amp;#8217;s assessment of such cases and potential exposure
involved relative to insurance coverage, except as otherwise noted
below, no provision has been made in Teva&amp;#8217;s financial
statements for any of such actions. Teva believes that none of the
proceedings described below will have a material adverse effect on
its financial condition; however, if one or more of such
proceedings were to result in judgments against Teva, such
judgments could be material to its results of operations in a given
period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;From time to time, Teva seeks
to develop generic products for sale prior to patent expiration in
various territories. In the United States, to obtain approval for
most generic products prior to the expiration of the
originator&amp;#8217;s patent(s), Teva must challenge the patent(s)
under the procedures set forth in the Hatch-Waxman Act of 1984, as
amended by the Medicare Prescription Drug Improvement and
Modernization Act of 2003. To the extent that it seeks to utilize
such patent challenge procedures, Teva is and expects to be
involved in patent litigation regarding the validity,
enforceability or infringement of the originator&amp;#8217;s patent(s).
Teva may also be involved in patent litigation involving the extent
to which alternate manufacturing process techniques may infringe
originator or third-party process patents. Additionally, depending
upon a complex analysis of a variety of legal and commercial
factors, Teva may, in certain circumstances, elect to market a
generic product even though litigation is still pending. This could
be before any court decision is rendered or while an appeal of a
lower court decision is pending. To the extent Teva elects to
proceed in this manner, it could face substantial liability for
patent infringement if the final court decision is adverse to Teva.
Although the underlying generic industry legislation, as well as
the patent law, is different in other countries where Teva does
business, from time to time Teva is also involved in litigation
regarding corresponding patents in those countries. Except as
described below, Teva does not have a reasonable basis to estimate
the loss, or range of loss, that is reasonably possible with
respect to such patent infringement cases. However, if Teva were to
be required to pay damages in any such case, courts would generally
calculate the amount of any such damages based on a reasonable
royalty or lost profits of the patentee. If damages were determined
based on lost profits, the amount would be related to the sales of
the branded product. In addition, the launch of an authorized
generic and other generic competition may be relevant to the
damages estimation.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Teva&amp;#8217;s business
inherently exposes it to potential product liability claims. Teva
believes that it maintains product liability insurance coverage in
amounts and with provisions that are reasonable and prudent in
light of its business and related risks. However, Teva sells, and
will continue to sell, pharmaceutical products that are not covered
by insurance and accordingly may be subject to claims that are not
covered by insurance as well as claims that exceed its policy
limits. Product liability coverage for pharmaceutical companies is
becoming more expensive and increasingly difficult to obtain. As a
result, Teva may not be able to obtain the type and amount of
coverage it desires.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In connection with
third-party agreements, Teva may under certain circumstances be
required to indemnify, and may be indemnified by, in unspecified
amounts, the parties to such agreements against third-party
claims.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;i&gt;Intellectual Property
Proceedings&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style=
"MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 3px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In October 2004, Alpharma and
Teva launched their 100 mg, 300 mg and 400 mg gabapentin capsule
products and, in December 2004, Alpharma and Teva launched their
600 mg and 800 mg gabapentin tablet products. Gabapentin capsules
and tablets are the AB-rated generic versions of Pfizer&amp;#8217;s
anticonvulsant Neurontin&lt;font face="Times New Roman" size=
"1"&gt;&lt;sup style=
"VERTICAL-ALIGN: baseline; BOTTOM: 0.8ex; POSITION: relative"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;
capsules and tablets, which had annual sales of approximately $2.7
billion for the twelve months ended September 2004, based on IMS
data. Teva&amp;#8217;s subsidiary Ivax also launched its non-AB rated
tablets in&lt;/font&gt;&amp;#160;&lt;font face="Times New Roman" size="2"&gt;August
2004 and its AB-rated capsules and tablets in March and April 2005,
respectively. In August&amp;#160;2005, the United States District Court
for the District of New Jersey granted summary judgment in favor of
Teva, Alpharma and Ivax. On September&amp;#160;21, 2007, the Court of
Appeals for the Federal Circuit (&amp;#8220;Federal Circuit&amp;#8221;)
reversed the summary judgment decision and remanded the case for
further proceedings. A trial has not been scheduled. The patent at
issue expires in 2017. Were Pfizer ultimately to be successful in
its allegation of patent infringement, Teva could be required to
pay damages and be enjoined from selling its gabapentin products.
Pursuant to the terms of the agreement with Alpharma, were Pfizer
to be successful in its allegation of patent infringement against
Alpharma, Teva may also be required to pay damages related to a
portion of the sales of Alpharma&amp;#8217;s gabapentin
products.&lt;/font&gt;&lt;/p&gt;
&lt;p style=
"MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 3px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In September and November
2004, Teva commenced sales of Impax Laboratories&amp;#8217; 20 mg and
10 mg omeprazole delayed release capsules, respectively, which are
the AB-rated generic versions of AstraZeneca&amp;#8217;s
Prilosec&lt;font face="Times New Roman" size="1"&gt;&lt;sup style=
"VERTICAL-ALIGN: baseline; BOTTOM: 0.8ex; POSITION: relative"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;
capsules. Prilosec&lt;font face="Times New Roman" size="1"&gt;&lt;sup style=
"VERTICAL-ALIGN: baseline; BOTTOM: 0.8ex; POSITION: relative"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;
had sales for the 10 mg capsule of $30 million and 20 mg capsule
sales of approximately $532 million, both for the twelve months
ended June 2004, based on IMS data. As provided for in a strategic
alliance agreement between Impax and Teva, the parties agreed to
certain risk-sharing arrangements relating to the omeprazole
launch. Trial in the United States District Court for the Southern
District of New York of AstraZeneca&amp;#8217;s patent infringement
litigation against Impax relating to its omeprazole capsules
concluded in June&amp;#160;2006. Following the expiration of the patent
in April&amp;#160;2007, the District Court issued a trial opinion in
which it found that Impax&amp;#8217;s omeprazole capsules infringed two
formulation patents and that those patents were valid. On
August&amp;#160;20, 2008, the Federal Circuit affirmed the District
Court&amp;#8217;s decision. A separate litigation against Teva with
respect to the launch of omeprazole capsules has been revived, but
no trial date has been scheduled. Were AstraZeneca ultimately to be
successful in its allegation of patent infringement, Teva and Impax
could be required to pay damages related to a portion of the sales
of Impax&amp;#8217;s omeprazole capsules.&lt;/font&gt;&lt;/p&gt;
&lt;p style=
"MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 3px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In May 2007, Teva commenced
sales of its 300 mg cefdinir capsule product and 125 mg/5 ml and
250 mg/5 ml cefdinir powder for oral suspension products. Cefdinir
capsules and cefdinir for oral suspension are the AB-rated generic
versions of Abbott&amp;#8217;s antibiotic Omnicef&lt;font face=
"Times New Roman" size="1"&gt;&lt;sup style=
"VERTICAL-ALIGN: baseline; BOTTOM: 0.8ex; POSITION: relative"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;,
which had annual sales of approximately $860 million for the twelve
months ended December 2006, based on IMS data. Teva is in
litigation with Abbott in the United States District Court for the
Northern District of Illinois with respect to a polymorph patent
that expires in 2011. In May&amp;#160;2007, the District Court denied
Abbott&amp;#8217;s motion for a preliminary injunction, finding that
Abbott was not likely to prevail on the merits as to Teva&amp;#8217;s
noninfringement defense, based on the record before the Court. On
May&amp;#160;18, 2009, the Federal Circuit affirmed the District
Court&amp;#8217;s denial of the preliminary injunction. No trial date
has been scheduled. Were Abbott ultimately to be successful in its
allegation of patent infringement, Teva could be required to pay
damages relating to sales of its cefdinir products and be enjoined
from selling those products.&lt;/font&gt;&lt;/p&gt;
&lt;p style=
"MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 3px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In May 2007, Teva commenced
sales of its 2.5mg/10mg, 5mg/10mg, 5mg/20mg, and 10mg/20mg
amlodipine besylate/benazepril capsules. Amlodipine
besylate/benazepril capsules are the AB-rated generic versions of
Novartis&amp;#8217; Lotrel&lt;font face="Times New Roman" size=
"1"&gt;&lt;sup style=
"VERTICAL-ALIGN: baseline; BOTTOM: 0.8ex; POSITION: relative"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;,
which had annual sales of approximately $1.4 billion for the twelve
months ended March 2007, based on IMS data. In June&amp;#160;2007, the
United States District Court for the District of New Jersey denied
Novartis&amp;#8217; motion for a preliminary injunction, finding that
Novartis was not likely to succeed on its allegations of
infringement. The patent at issue expires in 2017. A trial date has
not been scheduled. Were Novartis ultimately to be successful in
its allegation of patent infringement, Teva could be required to
pay damages related to sales of its amlodipine besylate/benazepril
capsules and be enjoined from selling those products.&lt;/font&gt;&lt;/p&gt;
&lt;p style=
"MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 3px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In June 2007, Novopharm,
Teva&amp;#8217;s Canadian subsidiary, commenced sales in Canada of its
2.5 mg, 5 mg, 7.5 mg, 10 mg and 15 mg olanzapine tablets, which are
the generic versions of Eli Lilly&amp;#8217;s Zyprexa&lt;font face=
"Times New Roman" size="1"&gt;&lt;sup style=
"VERTICAL-ALIGN: baseline; BOTTOM: 0.8ex; POSITION: relative"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;.
Zyprexa&lt;font face="Times New Roman" size="1"&gt;&lt;sup style=
"VERTICAL-ALIGN: baseline; BOTTOM: 0.8ex; POSITION: relative"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;
had annual sales in Canada of approximately $180 million for the
twelve months ended May 2007, based on IMS sales. In
June&amp;#160;2007, the Federal Court of Canada denied Eli
Lilly&amp;#8217;s request for an application to prohibit the Minister
of Health from issuing Novopharm&amp;#8217;s final regulatory approval.
Shortly after Novopharm&amp;#8217;s launch, Lilly filed an action for
patent infringement. The trial was completed on April&amp;#160;3, 2009.
The patent at issue expires on April&amp;#160;24, 2011. Were Eli Lilly
ultimately to be successful in its allegation of patent
infringement, Novopharm could be required to pay damages related to
its sales of olanzapine tablets and be enjoined from selling those
products.&lt;/font&gt;&lt;/p&gt;
&lt;p style=
"MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 3px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In September 2007, Teva
commenced sales of its 125 mg, 250 mg and 500 mg famciclovir
tablets, which are the AB-rated generic versions of Novartis&amp;#8217;
Famvir&lt;font face="Times New Roman" size="1"&gt;&lt;sup style=
"VERTICAL-ALIGN: baseline; BOTTOM: 0.8ex; POSITION: relative"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;.
Famvir&lt;font face="Times New Roman" size="1"&gt;&lt;sup style=
"VERTICAL-ALIGN: baseline; BOTTOM: 0.8ex; POSITION: relative"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;
had annual sales of approximately $200 million for the twelve
months ended June 2007. In September&amp;#160;2007, the United States
District Court for the District of New Jersey denied
Novartis&amp;#8217; motion for a preliminary injunction, finding that
Novartis was not likely to prevail on the merits as to Teva&amp;#8217;s
invalidity and inequitable conduct defenses, based on the record
before the Court. On June&amp;#160;9, 2008, the Federal Circuit denied
Novartis&amp;#8217; appeal of the denial of the preliminary injunction.
Trial is currently scheduled to begin on November&amp;#160;9, 2009.
Were Novartis ultimately to be successful in its allegation of
patent infringement, Teva could be required to pay damages relating
to the sale of its famciclovir tablets and be enjoined from selling
those products.&lt;/font&gt;&lt;/p&gt;
&lt;p style=
"MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 3px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In December 2007, Teva
commenced sales of its 20 mg and 40 mg pantoprazole sodium tablets.
Pantoprazole sodium tablets are the AB-rated generic versions of
Wyeth&amp;#8217;s Protonix&lt;font face="Times New Roman" size=
"1"&gt;&lt;sup style=
"VERTICAL-ALIGN: baseline; BOTTOM: 0.8ex; POSITION: relative"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;,
which had annual sales of approximately $2.5 billion for the twelve
months&lt;/font&gt;&amp;#160;&lt;font face="Times New Roman" size="2"&gt;ended
September 2007, based on IMS data. In September 2007, the United
States District Court for the District of New Jersey denied
Wyeth/Altana&amp;#8217;s motion for a preliminary injunction, finding
that Wyeth/Altana was not likely to prevail on the merits as to
Teva&amp;#8217;s invalidity defense, based on the record before the
Court. On May&amp;#160;14, 2009, the Federal Circuit affirmed the
District Court&amp;#8217;s denial of the preliminary injunction. The
patent at issue expires on January&amp;#160;19, 2011, including
pediatric exclusivity. A trial date has not been scheduled. Were
Wyeth/Altana ultimately to be successful in its allegation of
patent infringement, Teva could be required to pay damages relating
to the sale of its pantoprazole sodium tablets and be enjoined from
further selling those products.&lt;/font&gt;&lt;/p&gt;
&lt;p style=
"MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 3px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;On July&amp;#160;11, 2008, Teva
learned that Sandoz Inc., the U.S. generic drug division of
Novartis AG, in conjunction with Momenta Pharmaceuticals, Inc., had
filed an ANDA with the FDA for a generic version of
Copaxone&lt;font face="Times New Roman" size="1"&gt;&lt;sup style=
"VERTICAL-ALIGN: baseline; BOTTOM: 0.8ex; POSITION: relative"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;
(glatiramer acetate) containing Paragraph IV certifications to each
of the patents that Teva has listed in the FDA&amp;#8217;s Orange Book
for the product. On August&amp;#160;28, 2008, Teva filed a complaint
against Sandoz, Inc., Sandoz International GmbH, Novartis AG and
Momenta Pharmaceuticals, Inc. in the United States District Court
for the Southern District of New York, alleging infringement of
four Orange Book patents, as well as trade secret misappropriation
claims. The patents, which expire on May&amp;#160;24, 2014, cover the
chemical composition of Copaxone&lt;font face="Times New Roman" size=
"1"&gt;&lt;sup style=
"VERTICAL-ALIGN: baseline; BOTTOM: 0.8ex; POSITION: relative"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;,
pharmaceutical compositions containing it, and methods of using it.
The lawsuit has triggered a stay of any FDA approval of the Sandoz
ANDA until the earlier of the expiration of a period of 30 months
or a district court decision in Sandoz&amp;#8217;s favor. On
November&amp;#160;3, 2008, Sandoz, Inc. and Momenta Pharmaceuticals
Inc. filed their answers to Teva&amp;#8217;s complaint. The answers
assert several affirmative defenses to Teva&amp;#8217;s patent
infringement claims, including non-infringement, invalidity and
unenforceability of the asserted Orange Book patents. The answers
also seek declaratory judgments of non-infringement, invalidity and
unenforceability with respect to three unasserted Orange Book
patents and two non-Orange Book patents. On December&amp;#160;11, 2008,
Sandoz International GmbH and Novartis AG brought a motion to
dismiss Teva&amp;#8217;s patent claims on personal jurisdiction
grounds. Those defendants are also seeking to dismiss Teva&amp;#8217;s
trade secret misappropriation claims, alleging that the Court has
no jurisdiction over the trade secret claims. No trial date has
been scheduled.&lt;/font&gt;&lt;/p&gt;
&lt;p style=
"MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 3px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In August 2008, Barr
commenced sales of its 4 mg, 8 mg and 12 mg galantamine immediate
release (IR) tablets. Galantamine IR tablets are the AB-rated
generic versions of Ortho-McNeil and Janssen&amp;#8217;s
Razadyne&lt;font face="Times New Roman" size="1"&gt;&lt;sup style=
"VERTICAL-ALIGN: baseline; BOTTOM: 0.8ex; POSITION: relative"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;,
which had annual sales of approximately $98 million for the twelve
months ending September 2008, based on IMS data. Prior to launching
the product, the United States District Court for the District of
Delaware held that the one Orange Book method patent, which expired
in December 2008, was invalid. Oral argument on Ortho-McNeil and
Janssen&amp;#8217;s appeal was heard on June&amp;#160;3, 2009. Were
Ortho-McNeil and Janssen ultimately to be successful in their
allegations of patent infringement, Barr could be required to pay
damages relating to the sale of its galantamine IR
tablets.&lt;/font&gt;&lt;/p&gt;
&lt;p style=
"MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 3px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In October 2008, Barr
commenced sales of its 8 mg, 16 mg and 24 mg galantamine extended
release (ER) capsules. Galantamine ER capsules are the AB-rated
generic versions of Ortho-McNeil and Janssen&amp;#8217;s Razadyne
ER&lt;font face="Times New Roman" size="1"&gt;&lt;sup style=
"VERTICAL-ALIGN: baseline; BOTTOM: 0.8ex; POSITION: relative"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;,
which had annual sales of approximately $110 million for the twelve
months ending September 2008, based on IMS data. The case involved
two patents &amp;#8211; a formulation patent and a method patent. The
United States District Court for the District of New Jersey
dismissed the allegations with respect to the formulation patent.
The method patent was held invalid in the litigation involving
galantamine IR, and oral argument was heard on June&amp;#160;3, 2009.
Were Ortho-McNeil and Janssen ultimately to be successful in their
appeal of the method patent, Barr could be required to pay damages
relating to the sale of its galantamine ER capsules.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;i&gt;Product Liability
Matters&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Barr and Duramed have been
named as defendants in approximately 6,000 personal injury product
liability cases brought against them and other manufacturers by
plaintiffs claiming injuries from the use of certain estrogen and
progestin products. The cases primarily involve medroxyprogesterone
acetate (a progestin that has been prescribed to women receiving
estrogen-containing hormone therapy), and a much smaller number
involve Cenestin (an estrogen-containing product sometimes
prescribed to treat symptoms associated with menopause). A high
percentage of the plaintiffs were unable to demonstrate actual use
of a Barr or Duramed product. As a result, approximately 5,450
cases have been dismissed, leaving approximately 500 pending. To
date, Barr and Duramed products have been identified in 487 of
those cases. Additional dismissals are expected. Barr believes it
has viable defenses to the allegations in the complaints and is
defending the actions vigorously.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;i&gt;Commercial Matters&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size=
"2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;In
April&amp;#160;2004, Rhodes Technologies and Napp Technologies
(&amp;#8220;Rhodes/Napp&amp;#8221;) filed a complaint in Massachusetts
Superior Court, seeking an equal share of the value to Teva of the
settlement of certain claims between GlaxoSmithKline and Teva
relating to Teva&amp;#8217;s nabumetone products. The allegations are
based upon the termination of a nabumetone API supply agreement
between Teva and Rhodes/Napp. Teva originally assessed the value of
the product rights received in connection with the settlement at
$100 million and subsequently recorded impairment charges of $52
million in the aggregate relating to this product. Oral argument on
the parties&amp;#8217; cross-motions for summary judgment was held in
April 2006. In April 2007, the Superior Court granted Teva&amp;#8217;s
motion for summary judgment, dismissing Rhodes/Napp&amp;#8217;s claims
against Teva. On July&amp;#160;14, 2009, the Massachusetts Appeals
Court affirmed the granting of summary judgment in Teva&amp;#8217;s
favor. Rhodes/Napp may seek further appellate review of this
decision, but the review is discretionary, and not as of
right.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In October&amp;#160;2005,
plaintiffs Agvar Chemicals Inc., Ranbaxy Laboratories, Inc., and
Ranbaxy Pharmaceuticals, Inc. filed suit against Barr in the
Superior Court of New Jersey. In their complaint, plaintiffs sought
to recover damages and other relief, based on an alleged breach of
a contract whereby Barr was to purchase from Ranbaxy raw material
for its generic Allegra product. In February 2009, Barr settled its
claims with Agvar and in April it settled its claims with
Ranbaxy.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;i&gt;Environmental Matters&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Teva&amp;#8217;s subsidiaries,
including those in the United States and its territories, are party
to a number of proceedings brought under the Comprehensive
Environmental Response, Compensation and Liability Act, commonly
known as the Superfund law, or other national, federal, provincial
or similar state and local laws imposing liability for the
investigation and remediation of releases of hazardous substances
and for natural resource damages. These proceedings seek to require
the generators of hazardous wastes disposed of at a third-party
owned site, or the party responsible for a release of hazardous
substances into the environment that impacted a site, to
investigate and clean up the sites or to pay for such activities
and any related damages to natural resources. Teva has been made a
party to these proceedings, along with other potentially
responsible parties, as an alleged generator of wastes that were
disposed of or treated at third-party waste disposal sites, or as a
result of an alleged release from one of Teva&amp;#8217;s (or its
predecessors&amp;#8217;) facilities or former facilities that may have
adversely impacted a site. In many of these cases, the government
or private litigants allege that the responsible parties are
jointly and severally liable for the investigation and cleanup
costs. Although the liability among the responsible parties may be
joint and several, these proceedings are frequently resolved so
that the allocation of cleanup costs among the parties reflects the
relative contributions of the parties to the site conditions and
takes into account other equitable factors. Teva&amp;#8217;s potential
liability varies greatly at each of the sites in the proceedings;
for some sites the costs of the investigation, cleanup and natural
resource damages have not yet been determined, and for others
Teva&amp;#8217;s allocable share of liability has not been determined.
At other sites, Teva has been paying its share, but the amounts
have not been, and are not expected to be, material. Teva has taken
an active role in identifying these costs, which do not include
reductions for potential recoveries of cleanup costs from insurers,
former site owners or operators. While it is not feasible to
predict the outcome of many of these proceedings, Teva believes
that they should not ultimately result in any liability that would
have a material adverse effect on its financial position, results
of operations or liquidity and capital resources.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;i&gt;Competition, Pricing and Regulatory
Matters&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style=
"MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 3px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In April 2006, Teva and Barr
were sued, along with Cephalon, Inc., Mylan Laboratories, Inc.,
Ranbaxy Laboratories Ltd. and Ranbaxy Pharmaceuticals, Inc., in a
class action lawsuit filed in the United States District Court for
the Eastern District of Pennsylvania. The case alleges generally
that the settlement agreements entered into between the different
generic pharmaceutical companies and Cephalon, in their respective
patent infringement cases involving finished modafinil products
(the generic version of Provigil&lt;font face="Times New Roman" size=
"1"&gt;&lt;sup style=
"VERTICAL-ALIGN: baseline; BOTTOM: 0.8ex; POSITION: relative"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;),
were unlawful because the settlement agreements resulted in the
exclusion of generic competition. The case seeks unspecified
monetary damages, attorneys&amp;#8217; fees and costs. The case was
brought by King Drug Company of Florence, Inc. on behalf of itself
and as a proposed class action on behalf of any other person or
entity that purchased Provigil&lt;font face="Times New Roman" size=
"1"&gt;&lt;sup style=
"VERTICAL-ALIGN: baseline; BOTTOM: 0.8ex; POSITION: relative"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;
directly from Cephalon from January 2006 until the alleged unlawful
conduct ceases. Similar allegations have been made in a number of
additional complaints, including those filed on behalf of proposed
classes of direct and indirect purchasers of the product, by an
individual indirect purchaser of the product and by Apotex, Inc.
The cases seek various forms of injunctive and monetary relief,
including treble damages and attorneys&amp;#8217; fees and costs. In
February&amp;#160;2008, following an investigation of these matters,
the Federal Trade Commission (&amp;#8220;FTC&amp;#8221;) sued Cephalon,
alleging that Cephalon violated Section&amp;#160;5 of the Federal Trade
Commission Act, which prohibits unfair or deceptive acts or
practices in the marketplace, by unlawfully maintaining a monopoly
in the sale of Provigil&lt;font face="Times New Roman" size=
"1"&gt;&lt;sup style=
"VERTICAL-ALIGN: baseline; BOTTOM: 0.8ex; POSITION: relative"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;
and improperly excluding generic competition. The FTC&amp;#8217;s
complaint does not name Teva or Barr as a defendant.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Teva Pharmaceuticals USA,
Inc. (&amp;#8220;Teva USA&amp;#8221;) is a defendant, along with Biovail
Corp. and Elan Corporation, plc, in several civil actions currently
pending in the United States District Court for the District of
Columbia. The cases allege generally that arrangements between
Biovail and Elan relating to sales of nifedipine cc extended
release tablets, in connection with which Teva USA acted as a
distributor for Biovail, were unlawful under the federal antitrust
laws. The challenged arrangements were previously the subject of a
consent decree entered into by the FTC with Biovail and Elan, to
which Teva USA was not a party. The complaints seek unspecified
monetary damages, attorneys&amp;#8217; fees and costs. Four of the
cases were brought on behalf of alleged classes of persons who
allegedly purchased nifedipine cc extended release tablets made by
Elan or Biovail in the United States directly from Teva USA; two of
the cases were brought individually by alleged direct
purchasers.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Together with many other
pharmaceutical manufacturers, Teva and/or its subsidiaries in the
United States, including Teva USA, Sicor Inc.
(&amp;#8220;Sicor&amp;#8221;), Ivax, and Barr (collectively, the
&amp;#8220;Teva parties&amp;#8221;), are defendants in a number of cases
pending in state and federal courts throughout the country that
relate generally to drug price reporting by manufacturers. Such
price reporting is alleged to have caused governments and others to
pay inflated reimbursements for covered drugs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&amp;#160;&lt;/p&gt;
&lt;!-- 9 Repeat_Hdr_End * DO NOT REMOVE OR EDIT --&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Class actions and other cases
have been filed against over two dozen pharmaceutical
manufacturers, including Sicor, regarding allegedly inflated
reimbursements or payments under Medicare or certain insurance
plans. These cases were consolidated under the federal
multi-district litigation procedures and are currently pending in
the United States District Court for the District of Massachusetts
(the &amp;#8220;MDL&amp;#8221;). In March&amp;#160;2008, the &amp;#8220;Track
2&amp;#8221; defendants in the MDL, including Sicor, entered into a
settlement agreement to resolve the MDL. The court granted
preliminary approval of the amended MDL settlement in
July&amp;#160;2008 and deferred final approval of the settlement to
allow for the resolution of certain notice issues. Sicor is also a
defendant in an action brought under the federal False Claims Act,
but has not yet been served with the complaint. This matter is
under seal and includes many of the same defendants as the MDL. A
provision for these matters, including Sicor&amp;#8217;s share of the
MDL settlement payment, has been included in the financial
statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;A number of state attorneys
general, approximately 47 counties in New York and the City of New
York have also filed various actions relating to drug price
reporting. The Teva parties (either collectively or individually)
are currently involved in one or more actions relating to
reimbursements under Medicaid or other programs in the following 17
states: Alabama, Alaska, Arizona, Florida, Hawaii, Idaho, Illinois,
Iowa, Kansas, Kentucky, Mississippi, Missouri, New York, South
Carolina, Texas, Utah and Wisconsin. In addition to its action
relating to its Medicaid program, the state of South Carolina has
brought an action in the South Carolina state courts on behalf of
its state health plan. Sicor definitively settled the action
brought by the state of Arizona and certain Teva parties reached a
settlement in principle to resolve the action brought by the state
of Alabama. A provision has been included in the financial
statements for both settlements. Trials for certain Teva parties
have been scheduled for January 2010 in the Texas action and June
2010 in the Hawaii action.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In May 2008, the United
States District Court for the District of Massachusetts unsealed a
drug pricing action against several generic pharmaceutical
companies, including various Teva parties. The action was filed by
a private party pursuant to the federal False Claims Act, and it
alleges, on behalf of the federal government, drug pricing claims
arising from the federal government&amp;#8217;s contributions to the
various state Medicaid programs. According to the complaint, the
federal government declined to intervene in the litigation. The
foregoing drug pricing cases, which seek unspecified amounts in
money damages, civil penalties, treble damages, punitive damages,
attorneys fees, and/or administrative, injunctive, equitable or
other relief, are at various stages of litigation, and the Teva
parties continue to defend them vigorously.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;The Office of the United
States Attorney for the District of Massachusetts (the &amp;#8220;U.S.
Attorney&amp;#8221;) and the Civil Division of the Department of
Justice (the &amp;#8220;Civil Division&amp;#8221;) initiated an
investigation of allegations that IVAX Pharmaceuticals, Inc.
(&amp;#8220;IPI&amp;#8221;) caused Omnicare, Inc. to file false or tainted
claims for Medicare and/or Medicaid reimbursement, in violation of
law, by directly or indirectly offering or paying remuneration to
Omnicare, Inc., to induce it to recommend, prescribe or purchase
IPI&amp;#8217;s products. IPI cooperated in the investigation. In
April&amp;#160;2008, the U.S. Attorney advised IPI&amp;#8217;s counsel that
criminal charges would not be brought against IPI. The U.S.
Attorney and the Civil Division, however, continued their
investigation into potential violations of the False Claims Act.
IPI reached a settlement in principle with the U.S. Attorney and
the Civil Division, and a provision for the settlement amount has
been included in the financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Barr has been named as a
co-defendant with Bayer Corporation, The Rugby Group, Inc. and
others in approximately 38 class action complaints filed in state
and federal courts by direct and indirect purchasers of
Ciprofloxacin (Cipro) from 1997 to the present. The complaints
allege that a 1997 Bayer-Barr patent litigation settlement
agreement was anti-competitive and violated federal antitrust laws
and/or state antitrust and consumer protection laws. A prior
investigation of this agreement by the Texas Attorney
General&amp;#8217;s office on behalf of a group of state attorneys
general was closed without further action in December&amp;#160;2001. In
March&amp;#160;2005, the court in the federal multi-district litigation
granted summary judgment in Barr&amp;#8217;s favor and dismissed all of
the federal actions before it. In November&amp;#160;2007, the Second
Circuit transferred the appeal involving the indirect purchaser
plaintiffs to the United States Court of Appeals for the Federal
Circuit, while retaining jurisdiction over the appeals of the
direct purchaser plaintiffs. On October&amp;#160;15, 2008, the Federal
Circuit affirmed the grant of summary judgment in the
defendants&amp;#8217; favor on all claims by the indirect purchaser
plaintiffs. The plaintiffs&amp;#8217; petition for panel rehearing and
rehearing en banc was denied on December&amp;#160;23, 2008 and the
mandate issued on December&amp;#160;30, 2008. The plaintiffs filed a
petition for certiorari to the United States Supreme Court, which
was denied on June&amp;#160;22, 2009. Briefing in the direct purchaser
plaintiffs&amp;#8217; appeal in the Second Circuit is complete, and
oral argument was heard on April&amp;#160;28, 2009. All but three of
the state cases have been dismissed. Following an earlier stay of
the California case, the parties briefed summary judgment motions,
and oral argument on those motions is scheduled for August&amp;#160;21,
2009. The Kansas action is stayed, and the Florida action is in the
very early stages, with no hearings or schedule set to date. Barr
believes that its agreement with Bayer is a valid settlement to a
patent suit and cannot form the basis of an antitrust
claim.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;NOTE 7 &amp;#8211; Comprehensive
income:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Comprehensive income is as
follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; FONT-SIZE: 12px; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" align="center"
border="0"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="81%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="6"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;Three&amp;#160;months&amp;#160;ended&lt;br /&gt;
June&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="6"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;Six&amp;#160;months&amp;#160;ended&lt;br /&gt;
June&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="14"&gt;&lt;font face="Times New Roman" size="1"&gt;&lt;b&gt;U.S.
$ in millions&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Net income attributable to
Teva&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;521&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;533&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;972&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;672&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Other comprehensive income, net of
tax:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Unrealized gain (loss) from
available-for-sale securities, net of tax&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;58&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(54&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(7&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(128&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Reclassification adjustment on available
for sale securities, net of tax&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(7&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;36&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;*&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(7&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;82&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;*&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Currency translation adjustment, net of
tax&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;527&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;145&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(86&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;736&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="+0"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;1,099&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;660&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;872&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;1,362&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="+0"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style=
"MARGIN-TOP: 0px; MARGIN-BOTTOM: 2px; WIDTH: 10%; LINE-HEIGHT: 8px; BORDER-BOTTOM: #000000 0.5pt solid"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0"
cellpadding="0" width="100%" border="0"&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td valign="top" align="left" width="4%"&gt;&lt;font face=
"Times New Roman" size="2"&gt;*&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font face="Times New Roman" size=
"2"&gt;Represents mainly the unrealized loss on marketable securities
valued using Level 3 inputs, which was considered other than
temporary and charged to the statement of income.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;The above amounts are after deducting
amounts attributable to non-controlling interest, which were not
material.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:ComprehensiveIncomeNoteTextBlock>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;NOTE 4 &amp;#8211; Convertible senior
debentures:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;During the six months ended
June&amp;#160;30, 2009, $719 million principal amount of convertible
senior debentures were converted into approximately 20&amp;#160;million
Teva shares. Out of the $719&amp;#160;million principle amount,
approximately $354&amp;#160;million principal amount is related to 0.5%
convertible senior debentures due 2024 and $365&amp;#160;million
principal amount is related to 0.25% convertible senior debentures
due 2024.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:AssetImpairmentCharges contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">2000000</us-gaap:AssetImpairmentCharges>
  <us-gaap:CostOfGoodsAndServicesSold contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">3207000000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">-137000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">414000000</us-gaap:DepreciationAndAmortization>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">-12000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">6000000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;NOTE 9 &amp;#8211; Fair value
measurement:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Effective January&amp;#160;1,
2008, the Company adopted SFAS No.&amp;#160;157, &amp;#8220;Fair Value
Measurements&amp;#8221; (&amp;#8220;SFAS No.&amp;#160;157&amp;#8221;), for
financial assets and liabilities, and related Financial Staff
Positions (FSPs), including FSP FAS 157-3, &amp;#8220;Determining the
Fair Value of a Financial Asset When the Market for That Asset Is
Not Active&amp;#8221; (&amp;#8220;FSP FAS 157-3&amp;#8221;). This pronouncement
defines fair value, establishes a framework for measuring fair
value and expands disclosures about fair value measurements. As
defined in SFAS No.&amp;#160;157 and clarified by FSP FAS 157-3, fair
value is based on the price that would be received to sell an asset
or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. Additionally,
effective January&amp;#160;1, 2009, the Company implemented SFAS
No.&amp;#160;157 for non-financial assets and liabilities as well. The
adoption did not have a significant effect on these financial
statements. In April 2009, the FASB issued FSP FAS 157-4,
&amp;#8220;Determining Whether a Market Is Not Active and a Transaction
Is Not Distressed&amp;#8221;. FSP FAS 157-4 provides additional
guidance on factors to consider when estimating fair value
consequent to a significant decrease in market activity for a
financial asset. As applicable for Teva, this standard became
effective for interim and annual periods ending after June&amp;#160;15,
2009. The adoption of this standard did not have a material impact
on the Company&amp;#8217;s consolidated financial
statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In order to increase
consistency and comparability in fair value measurements, SFAS
No.&amp;#160;157 establishes a fair value hierarchy that prioritizes
observable and unobservable inputs used to measure fair value into
three broad levels, which are described below:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Level 1: Quoted prices
(unadjusted) in active markets that are accessible at the
measurement date for assets or liabilities. The fair value
hierarchy gives the highest priority to Level 1 inputs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Level 2: Observable prices
that are based on inputs not quoted on active markets, but
corroborated by market data.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Level 3: Unobservable inputs
are used when little or no market data is available. The fair value
hierarchy gives the lowest priority to Level 3 inputs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In determining fair value,
the Company utilizes valuation techniques that maximize the use of
observable inputs and minimize the use of unobservable inputs to
the extent possible and considers counterparty credit risk in its
assessment of fair value.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;!-- 9 Repeat_Hdr_End * DO NOT REMOVE OR EDIT --&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Financial items carried at
fair value as of June&amp;#160;30, 2009 are classified in the table
below in one of the three categories described above:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; FONT-SIZE: 12px; MARGIN-BOTTOM: 0px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" align="center"
border="0"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="80%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="11"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;June&amp;#160;30, 2009&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font face="Times New Roman" size="1"&gt;&lt;b&gt;U.S. $ in
millions&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;Level&amp;#160;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;Level&amp;#160;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;Level&amp;#160;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Cash and cash equivalents:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Money markets&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;490&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;490&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Mainly cash deposits&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;1,271&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;1,271&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Marketable securities**&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Auction rate securities&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;75&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;75&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Collateral debt obligations&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;12&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;*&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;*&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;12&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Equity securities&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;61&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;61&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Structures&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;36&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;36&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;34&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;34&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Derivatives &amp;#8211; net***&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;61&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;61&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;1,868&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;97&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;75&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;2,040&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style=
"MARGIN-TOP: 0px; MARGIN-BOTTOM: 2px; WIDTH: 10%; LINE-HEIGHT: 8px; BORDER-BOTTOM: #000000 0.5pt solid"&gt;
&amp;#160;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0"
cellpadding="0" width="100%" border="0"&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td valign="top" align="left" width="4%"&gt;&lt;font face=
"Times New Roman" size="2"&gt;*&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font face="Times New Roman" size=
"2"&gt;Represents an amount of less than $0.5 million.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0"
cellpadding="0" width="100%" border="0"&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td valign="top" align="left" width="4%"&gt;&lt;font face=
"Times New Roman" size="2"&gt;**&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font face="Times New Roman" size=
"2"&gt;Marketable securities consist mainly of debt securities
classified as available-for-sale and are recorded at fair value.
The fair value of quoted securities is based on current market
value (Level 1 input) or observable prices (Level 2 input). When
securities do not have an active market or observable prices, fair
value is determined using a valuation model (Level 3 input). This
model is based on reference to other instruments with similar
characteristics, or a discounted cash flow analysis, or other
pricing models making use of market inputs and relying as little as
possible on entity-specific inputs.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0"
cellpadding="0" width="100%" border="0"&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td valign="top" align="left" width="4%"&gt;&lt;font face=
"Times New Roman" size="2"&gt;***&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font face="Times New Roman" size=
"2"&gt;Derivatives primarily represent foreign currency and option
contracts and interest rate swaps which are valued primarily based
on observable inputs including interest rate curves and both
forward and spot prices for currencies.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;The following table
summarizes the activity for those financial assets where fair value
measurements are estimated utilizing Level 3 inputs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; FONT-SIZE: 12px; MARGIN-BOTTOM: 0px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" align="center"
border="0"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="88%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;June&amp;#160;30, 2009&lt;br /&gt;
U.S.&amp;#160;$&amp;#160;in&amp;#160;millions&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Carrying value as of January&amp;#160;1,
2009&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;98&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Amount realized&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(3&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Net change to fair value included in
other comprehensive income&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(20&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td height="8"&gt;&lt;/td&gt;
&lt;td colspan="4" height="8"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Carrying value as of June&amp;#160;30,
2009&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;75&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In April 2009, the FASB
issued FSP FAS 107-1 and APB 28-1, &amp;#8220;Interim Disclosures About
Fair Value of Financial Instruments&amp;#8221; (FSP FAS 107-1 and APB
28-1). FSP FAS 107-1 and APB 28-1 require fair value disclosures in
both interim as well as annual financial statements in order to
provide more timely information about the effects of current market
conditions on financial statements. As applicable for Teva, FSP FAS
107-1 and APB 28-1 are effective for interim and annual periods
ending after June&amp;#160;15, 2009. The fair values and the carrying
amounts of derivatives and senior convertible notes and debentures
with an earliest date of redemption within 12 months are assets of
$87 million and liabilities of $986 million at June&amp;#160;30, 2009.
The fair value of derivatives generally reflects the estimated
amounts that Teva would receive or pay to terminate the contracts
at the reporting dates.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;The financial instruments of
the Company consist mainly of cash and cash equivalents, marketable
securities, current and non-current receivables, short-term credit,
accounts payable and accruals, long-term loans and other long-term
senior notes and loans, convertible senior debentures and
derivatives.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size=
"2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The fair value
of the financial instruments included in working capital and
non-current receivables of the Company is usually identical or
close to their carrying value. The fair value of long-term bank
loans and senior notes also approximates their carrying value,
since they bear interest at rates close to the prevailing market
rates. The fair value of the convertible senior notes and
debentures, included under long-term liabilities, based on quoted
market values and prevailing market rates, amounted to $2,611
million at June&amp;#160;30, 2009.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;!-- 9 Repeat_Hdr_End * DO NOT REMOVE OR EDIT --&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Changes in fair value of
available for sale securities, net of taxes, are reflected in other
comprehensive income. Unrealized losses considered to be temporary
are reflected in other comprehensive income; unrealized losses that
are considered to be other-than-temporary are charged to income as
an impairment charge. On June, 15, 2009, the Company adopted FAS
115-2 and FAS 124-2, &amp;#8220;Recognition and Presentation of
Other-Than-Temporary Impairments&amp;#8221; (FSP FAS 115-2 and FAS
124-2). FSP FAS 115-2 and FAS 124-2 change the method for
determining whether an other-than-temporary impairment exists for
debt securities and the amount of the impairment to be recorded in
earnings. The adoption of FASP FAS 115-2 and FAS 124-2 did not have
a material impact on the Company&amp;#8217;s financial
statements.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">393000000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GrossProfit contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">3340000000</us-gaap:GrossProfit>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">1116000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">-19000000</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">123000000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInOperatingCapital contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">-54000000</us-gaap:IncreaseDecreaseInOperatingCapital>
  <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">-61000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
  <us-gaap:InventoryDisclosureTextBlock contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;NOTE 3 &amp;#8211;
Inventories:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Inventories consisted of the
following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; FONT-SIZE: 12px; MARGIN-BOTTOM: 0px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="92%" align="center"
border="0"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="80%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;June&amp;#160;30,&lt;br /&gt;
2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;December&amp;#160;31,&lt;br /&gt;
2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="5"&gt;&lt;font face="Times New Roman" size="1"&gt;&lt;b&gt;U.S.
$ in millions&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="middle" colspan="2"&gt;&lt;font face=
"Times New Roman" size="1"&gt;&lt;b&gt;Unaudited&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="middle" colspan="2"&gt;&lt;font face=
"Times New Roman" size="1"&gt;&lt;b&gt;Audited&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Raw and packaging materials&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;1,152&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;903&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Products in process&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;561&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;559&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Finished products&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;1,670&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;1,904&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;3,383&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;3,366&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Materials in transit and payments on
account&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;113&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;30&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;3,496&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;3,396&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;/div&gt;

</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">-1155000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">-317000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">1391000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">972000000</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">-124000000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">1240000000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" align="center"&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;NOTE 1 &amp;#8211; Basis of
presentation:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;The accompanying unaudited
condensed consolidated financial statements have been prepared on
the same basis, with the exception of the adoption of FASB Staff
Position No. APB 14-1 as explained in note 10(a), as the annual
consolidated financial statements and, in the opinion of
management, reflects all adjustments, which include only normal
recurring adjustments, necessary to present fairly the financial
position and results of operations of Teva Pharmaceutical
Industries Limited (&amp;#8220;Teva&amp;#8221; or the
&amp;#8220;Company&amp;#8221;). These consolidated financial statements and
notes thereto are unaudited and should be read in conjunction with
the Company&amp;#8217;s audited financial statements included in its
Annual Report on Form 20-F for the year ended December&amp;#160;31,
2008, as filed with the Securities and Exchange Commission. The
results of operations for the three months and six months ended
June&amp;#160;30, 2009 are not necessarily indicative of results that
could be expected for the entire fiscal year.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">8000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsOfDividends contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">261000000</us-gaap:PaymentsOfDividends>
  <us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">0</us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">40000000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">311000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromRepaymentsOfShortTermDebt contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">-13000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">277000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">42000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">74000000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;NOTE 2 &amp;#8211; Certain
transactions:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;a. Acquisition of Barr
Pharmaceuticals, Inc.&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;On December&amp;#160;23, 2008,
the Company completed the acquisition of Barr Pharmaceuticals, Inc.
(&amp;#8220;Barr&amp;#8221;), a U.S.-based multinational generic
pharmaceutical company with operations mainly in the United States
and Europe, for approximately $4.6 billion in cash and
69&amp;#160;million shares. For accounting purposes, the transaction
was valued at approximately $7.5 billion, based on the average
value of our shares during the five trading day period commencing
two trading days before the date of the merger agreement. In
addition, Barr&amp;#8217;s net debt as of the acquisition date was
approximately $1.5 billion.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;The consideration for the
acquisition was attributed to net assets on the basis of fair value
of assets acquired and liabilities assumed. This allocation has not
been finalized.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Restructuring provisions
recorded were $320 million, mainly related to employee severance,
termination of certain agreements and other exit costs, of which
approximately $103 million has been paid through June&amp;#160;30,
2009.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Barr&amp;#8217;s results of
operations are included in the consolidated financial statements of
Teva commencing January&amp;#160;1, 2009.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;b. Lonza cooperation
agreement&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;On January&amp;#160;20, 2009,
Teva signed a definitive agreement with Lonza Group Ltd. to
establish a joint venture to develop, manufacture and market
generic equivalents of a selected portfolio of biologic
pharmaceuticals. The joint venture, TL Biopharmaceuticals AG,
commenced activities in May 2009. In connection with the formation
of the joint venture, Teva was reimbursed for related R&amp;amp;D
efforts it previously incurred. This reimbursement has been
recorded as a reduction in research and development
expenses.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Teva records its share of the
joint venture under share in losses of associated
companies.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:RepaymentsOfConvertibleDebt contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">0</us-gaap:RepaymentsOfConvertibleDebt>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">118000000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:RepaymentsOfOtherDebt contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">1120000000</us-gaap:RepaymentsOfOtherDebt>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">388000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">0</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">66000000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;NOTE 6 &amp;#8211; Revenue
recognition:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Revenue is recognized when
title to, and risk and reward for, a given product are transferred
to the customer, with provisions for estimated chargebacks,
returns, rebates, discounts and shelf stock adjustments established
concurrently with the recognition of revenue, and deducted from
sales.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Provisions for chargebacks,
returns, rebates and other promotional items are included in
&amp;#8220;sales reserves and allowances&amp;#8221; under current
liabilities. Provision for doubtful debts and prompt payment
discounts are netted against &amp;#8220;Accounts
receivable.&amp;#8221;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;The calculation is based on
historical experience and the specific terms in the individual
agreements. Chargebacks are the largest component of sales reserves
and allowances. Provisions for estimating chargebacks are
determined using historical chargeback experience, or expected
chargeback levels and wholesaler sales information for new
products, which are compared to externally obtained distribution
channel reports for reasonableness. Shelf-stock adjustments are
granted to customers based on the existing inventory of a customer
following actual or anticipated decreases in the invoice or
contract price of the related product. Where there is a historical
experience to customer returns, Teva records a reserve for
estimated sales returns by applying that experience to the amounts
invoiced and the amount of returned products to be destroyed versus
product that can be placed back in inventory for resale.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:SalesRevenueNet contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">6547000000</us-gaap:SalesRevenueNet>
  <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;NOTE 10 &amp;#8211; Recently adopted
accounting pronouncements:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;(a) - Accounting for convertible debt
instruments that may be settled in cash upon
conversion:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Effective January&amp;#160;1,
2009, the Company adopted FASB Staff Position No. APB 14-1,
&amp;#8220;Accounting for Convertible Debt Instruments That May Be
Settled in Cash upon Conversion (Including Partial Cash
Settlement)&amp;#8221;. The FSP was issued in May 2008, and requires
issuers to account separately for the liability and equity
components of convertible debt instruments that may be settled in
cash (including partial cash settlement), in a manner that reflects
the issuer&amp;#8217;s nonconvertible debt (unsecured debt) borrowing
rate when interest cost is recognized. The FSP requires bifurcation
of a component of the debt, classification of that component in
equity and accretion of the resulting discount on the debt to be
recognized as part of interest expense in the consolidated
statement of operations. The FSP requires retroactive application
to the terms of instruments as they existed for all periods
presented. The adoption of this FSP primarily affects the
accounting for the Company&amp;#8217;s 0.25% Senior Convertible
Debentures due 2026 and 1.75% Senior Convertible Debentures due
2026.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;The retroactive application
of this FSP resulted in (i)&amp;#160;an increase in the opening balance
in 2009 of additional paid-in capital and a decrease in retained
earnings of $175 million and $97 million, respectively,
(ii)&amp;#160;an increase in financial expenses for the three months
and six months ended June&amp;#160;30, 2008 of $6 million and $15
million, respectively, (iii)&amp;#160;a decrease in income taxes for
the three months and six months ended June&amp;#160;30, 2008 of an
amount of less than $0.5 million and $1 million, respectively, and
(iv)&amp;#160;a decrease in basic earnings per share of $0.01 and $0.02
for the three months and six months ended June&amp;#160;30, 2008,
respectively, and a decrease in diluted earnings per share of $0.01
for the six months ended June&amp;#160;30, 2009.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;!-- 9 Repeat_Hdr_End * DO NOT REMOVE OR EDIT --&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;(b) - Derivative instruments and
hedging activities:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Effective January&amp;#160;1,
2009, the Company adopted Statement of Financial Accounting
Standard No. 161 (&amp;#8220;FAS 161&amp;#8221;), Disclosures about
Derivative Instruments and Hedging Activities, as an amendment to
SFAS No.&amp;#160;133, Accounting for Derivative Instruments and
Hedging Activities. FAS 161 was issued in March 2008 and requires
that objectives for using derivative instruments be disclosed in
terms of underlying risk and accounting designation.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;The fair value of derivative
instruments is comprised of:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; FONT-SIZE: 6px; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0"
cellpadding="0" width="100%" border="0"&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="4%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left" width="4%"&gt;&lt;font face=
"Times New Roman" size="2"&gt;1.&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font face="Times New Roman" size=
"2"&gt;Asset derivatives, comprising foreign exchange contracts,
designated as hedging instruments under FAS 133. These are reported
under prepaid expenses and other current assets, and the fair value
amounted to less than $0.5 million and $13 million at June&amp;#160;30,
2009 and December&amp;#160;31, 2008, respectively.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 0px; FONT-SIZE: 6px; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0"
cellpadding="0" width="100%" border="0"&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="4%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left" width="4%"&gt;&lt;font face=
"Times New Roman" size="2"&gt;2.&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font face="Times New Roman" size=
"2"&gt;Asset derivatives, comprising primarily foreign exchange
contracts, not designated as hedging instruments under FAS 133.
These are reported under prepaid expenses and other current assets,
and the fair value amounted to $87 million and $52 million at
June&amp;#160;30, 2009 and December&amp;#160;31, 2008,
respectively.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 0px; FONT-SIZE: 6px; MARGIN-BOTTOM: 0px"&gt;
&lt;font size="+0"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0"
cellpadding="0" width="100%" border="0"&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="4%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left" width="4%"&gt;&lt;font face=
"Times New Roman" size="2"&gt;3.&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font face="Times New Roman" size=
"2"&gt;Liability derivatives, comprising foreign exchange contracts,
not designated as hedging instruments under FAS 133. These are
reported under accounts payable, and the fair value amounted to $26
million and $126 million at June&amp;#160;30, 2009 and
December&amp;#160;31, 2008, respectively.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Derivatives on foreign
exchange contracts not designated as hedging instruments under FAS
133, which hedge Teva&amp;#8217;s balance sheet items from currency
exposure, were recognized under financial expenses in the amount of
a loss of $70 million and a gain of $169 million for the six months
ended June&amp;#160;30, 2009 and June&amp;#160;30, 2008, respectively, and
a gain of $56 million and a gain of $117 million for the three
months ended June&amp;#160;30, 2009 and June&amp;#160;30, 2008,
respectively. Such gains or losses offset the revaluation of the
balance sheet items booked also under financial expenses. The
impact of derivatives designated as hedging instruments under FAS
133 was not material.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;(c) - Other recently adopted
accounting pronouncements:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In November 2008, the FASB
ratified EITF issue No.&amp;#160;08-07, &amp;#8220;Accounting for Defensive
Intangible Assets&amp;#8221; (EITF 08-7). EITF 08-7 gives guidance for
accounting for defensive intangible assets subsequent to their
acquisition in accordance with SFAS No.&amp;#160;141R and SFAS
No.&amp;#160;157, including the estimated useful life that should be
assigned to such assets. EITF 08-7 is effective for intangible
assets acquired on or after the beginning of the first annual
reporting period beginning on or after December&amp;#160;15, 2008. The
implementation of this standard did not have a material impact on
the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In April 2008, the FASB
issued FSP 142-3, &amp;#8220;Determination of the Useful Life of
Intangible Assets&amp;#8221; (&amp;#8220;FSP 142-3&amp;#8221;). FSP 142-3
amends the factors that should be considered in developing renewal
or extension assumptions on legal and contractual provisions used
to determine the useful life of a recognized intangible asset under
SFAS No.&amp;#160;142, &amp;#8220;Goodwill and Other Intangible
Assets&amp;#8221;. FSP 142-3 is effective for fiscal years beginning
after December&amp;#160;15, 2008. The implementation of this standard
did not have a material impact on the Company&amp;#8217;s consolidated
financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In December 2007, the FASB
issued SFAS No.&amp;#160;141 (revised 2007), &amp;#8220;Business
Combinations&amp;#8221; (&amp;#8220;FAS 141R&amp;#8221;). FAS 141R provides
revised guidance on how acquirers recognize and measure the
consideration, identifiable assets acquired, liabilities assumed,
contingencies, non-controlling interests and goodwill acquired in a
business combination, and expands disclosure requirements
surrounding the nature and financial effects of business
combinations. Key changes include: acquired in-process research and
development will no longer be expensed on acquisition, but
capitalized and assessed for impairment where relevant and
amortized over its useful life; acquisition costs will be expensed
as incurred; restructuring costs will generally be expensed in
periods after the acquisition date; the consideration in shares
would be valued at the closing date; and in the event that a
deferred tax valuation allowance relating to a business
acquisition, including from prior years, is subsequently reduced,
the adjustment will be recognized in the statement of income. Early
adoption is not permitted. As applicable to Teva, this statement
became effective, on a prospective basis, as of January&amp;#160;1,
2009. The adoption of FAS 141R did not have a material impact on
the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In December 2007, the FASB
issued SFAS No.&amp;#160;160, &amp;#8220;Noncontrolling Interests in
Consolidated Financial Statements&amp;#8212;an amendment of Accounting
Research Bulletin 51&amp;#8221; (&amp;#8220;FAS 160&amp;#8221;), which
establishes accounting and reporting standards for non-controlling
interests in a subsidiary and deconsolidation of a subsidiary.
Early adoption is not permitted. As applicable to Teva, this
statement became effective as of January&amp;#160;1, 2009. The adoption
of FAS 160 did not have a material impact on the Company&amp;#8217;s
consolidated financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;!-- 9 Repeat_Hdr_End * DO NOT REMOVE OR EDIT --&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In May 2009, the FASB issued
SFAS No.165, &amp;#8220;Subsequent Events&amp;#8221; (&amp;#8220;FAS
165&amp;#8221;), which establishes general standards of accounting for
and disclosure of events that occur after the balance sheet date
but before financial statements are issued or are available to be
issued. As applicable to Teva, this Statement became effective as
of June&amp;#160;15, 2009. In accordance with FAS 165, the Company has
evaluated subsequent events up to the filling date of these
financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
  <us-gaap:SegmentReportingDisclosureTextBlock contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;NOTE 8 &amp;#8211; Financial information
by business segments:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Financial reports to
Teva&amp;#8217;s chief operating decision maker evolve over time as
Teva&amp;#8217;s business develops and following major acquisitions.
Historically, Teva presented two reportable segments:
Pharmaceutical and Active Pharmaceutical Ingredients (API). In
2009, following the acquisition of Barr at the end of 2008, Teva
commenced certain organizational changes. Following the completion
of these changes, the Company intends to re-evaluate its segment
reporting in light of such changes. For purposes of this interim
report, Teva has reported two operating segments as in the
past.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;a. Financial data relating to reportable
operating segments:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; FONT-SIZE: 12px; MARGIN-BOTTOM: 0px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" align="center"
border="0"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="78%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;Pharmaceutical&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;API&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="8"&gt;&lt;font face="Times New Roman" size="1"&gt;&lt;b&gt;U.S.
$ in millions&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Three months ended June&amp;#160;30,
2009:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Net sales:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;To unaffiliated customers&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;3,265&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;135&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;3,400&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Intersegment&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;198&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;198&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Total net sales&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;3,265&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;333&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;3,598&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Operating income&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;588&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;178&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;766&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Depreciation and amortization&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;216&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;34&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;250&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Three months ended June&amp;#160;30,
2008:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Net sales:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;To unaffiliated customers&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;2,667&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;156&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;2,823&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Intersegment&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;296&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;296&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Total net sales&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;2,667&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;452&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;3,119&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Operating income&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;503&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;208&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;711&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Depreciation and amortization&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;91&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;28&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;119&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Six months ended June&amp;#160;30,
2009:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Net sales:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;To unaffiliated customers&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;6,254&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;293&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;6,547&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Intersegment&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;407&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;407&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Total net sales&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;6,254&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;700&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;6,954&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Operating income&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;1,025&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;323&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;1,348&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Depreciation and amortization&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;340&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;61&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;401&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;td colspan="3" height="8"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Six months ended June&amp;#160;30,
2008:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Net sales:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;To unaffiliated customers&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;5,086&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;309&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;5,395&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Intersegment&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;653&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;653&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Total net sales&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;5,086&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;962&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;6,048&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Operating income*&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;596&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;469&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;1,065&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Depreciation and amortization&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;187&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;53&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;240&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style=
"MARGIN-TOP: 0px; MARGIN-BOTTOM: 2px; WIDTH: 10%; LINE-HEIGHT: 8px; BORDER-BOTTOM: #000000 0.5pt solid"&gt;
&amp;#160;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" cellspacing="0"
cellpadding="0" width="100%" border="0"&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td valign="top" align="left" width="4%"&gt;&lt;font face=
"Times New Roman" size="2"&gt;*&lt;/font&gt;&lt;/td&gt;
&lt;td valign="top" align="left"&gt;&lt;font face="Times New Roman" size=
"2"&gt;Operating income for the six months ended June&amp;#160;30, 2008 of
the pharmaceutical segment included a charge of $382 million
relating to the acquisition of research and development in process
as part of the CoGenesys acquisition.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font size=
"1"&gt;&amp;#160;&lt;/font&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;!-- 9 Repeat_Hdr_End * DO NOT REMOVE OR EDIT --&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;b. The following is a reconciliation of
operating income and assets of the reportable segments to the data
included in the condensed consolidated financial
statements:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; FONT-SIZE: 12px; MARGIN-BOTTOM: 0px"&gt;
&amp;#160;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" align="center"
border="0"&gt;&lt;!-- 5 First_Row * DO NOT REMOVE OR EDIT --&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td width="76%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="6"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;Three&amp;#160;months&amp;#160;ended&lt;br /&gt;
June&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="6"&gt;&lt;font face="Times New Roman" size="1"&gt;&lt;b&gt;Six
months ended&lt;br /&gt;
June&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="14"&gt;&lt;font face="Times New Roman" size="1"&gt;&lt;b&gt;U.S.
$ in millions&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" align=
"middle" colspan="2"&gt;&lt;font face="Times New Roman" size=
"1"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Total operating income:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Reportable segments&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;766&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;711&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;1,348&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;1,065&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Amounts not allocated to
segments:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Profits not yet realized&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(43&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(47&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(62&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(61&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;General and administration
expenses&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(21&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(7&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(46&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(36&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Other expenses&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(19&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(33&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Financial expenses &amp;#8211;
net&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(61&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(34&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(124&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;(100&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;&lt;font face=
"Times New Roman" size="2"&gt;Consolidated income before income
taxes&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;641&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;604&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;1,116&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font face="Times New Roman" size=
"2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font face="Times New Roman"
size="2"&gt;835&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font face="Times New Roman"
size="2"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- 6 Last_Row * DO NOT REMOVE OR EDIT --&gt;&lt;/tbody&gt;
&lt;/table&gt;
&lt;/div&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
  <us-gaap:SellingAndMarketingExpense contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">1253000000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">25000000</us-gaap:ShareBasedCompensation>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="Shares" decimals="-6">895000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="Shares" decimals="-6">858000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <teva:IncomeBeforeMinorityInterestEarningsLossEquityInvestments contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">993000000</teva:IncomeBeforeMinorityInterestEarningsLossEquityInvestments>
  <teva:SupplementalDisclosuresTextBlock contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;Supplemental disclosure of non-cash
financing activities:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;During the six months ended
June&amp;#160;30, 2009, $719 million principal amount of convertible
senior debentures were converted into approximately 20&amp;#160;million
Teva shares.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</teva:SupplementalDisclosuresTextBlock>
  <teva:AdjustmentResearchAndDevelopmentInProcess contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">0</teva:AdjustmentResearchAndDevelopmentInProcess>
  <teva:DescriptionOfNewAccountingPronouncementsNotYetAdoptedTextBlock contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;NOTE 11 &amp;#8211; Recently issued
accounting pronouncement&lt;/b&gt;:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In June 2009, the FASB issued
SFAS No.168, &amp;#8220;Accounting Standard Codification&amp;#8221;
(&amp;#8220;FAS 168&amp;#8221;). FAS 168 will become the single
authoritative source for U.S. generally accepted accounting
principles (GAAP) and will change the way in which the accounting
literature is organized. As applicable to Teva, FAS 168 will be
effective commencing September&amp;#160;15, 2009.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</teva:DescriptionOfNewAccountingPronouncementsNotYetAdoptedTextBlock>
  <teva:ProfitLoss contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">974000000</teva:ProfitLoss>
  <teva:NetIncomeLossAttributableToNoncontrollingInterest contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0" unitRef="USD" decimals="-6">2000000</teva:NetIncomeLossAttributableToNoncontrollingInterest>
  <teva:EarningsPerShareTextBlock contextRef="eol_PE3710----096-K-0007_STD_p6m_20090630_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font face=
"Times New Roman" size="2"&gt;&lt;b&gt;NOTE 5 &amp;#8211; Earnings per
share:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;Basic earnings per share is
computed by dividing net income attributable to Teva by the
weighted average number of ordinary shares (including special
shares exchangeable into ordinary shares) outstanding during the
period, net of treasury shares.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In computing diluted earnings
per share for the three months and six months ended June&amp;#160;30,
2009 and 2008, respectively, basic earnings per share was adjusted
to take into account the potential dilution that could occur upon:
(1)&amp;#160;the conversion of the convertible senior debentures, using
the if-converted method, by adding to net income attributable to
Teva interest expense on these debentures, and amortization of
issuance costs, net of tax benefits, and by adding to the number of
shares the weighted average number of shares issuable upon assumed
conversion of these debentures; and (2)&amp;#160;the exercise of
options and restricted stock units granted under employee stock
compensation plans, using the treasury stock method.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; TEXT-INDENT: 4%"&gt;
&lt;font face="Times New Roman" size="2"&gt;In computing diluted earnings
per share for the three months and six months ended June&amp;#160;30,
2009 and for the six months ended June&amp;#160;30, 2008, no account
was taken of the potential dilution of the convertible senior
debentures, amounting to 16&amp;#160;million weighted average shares,
since they had an anti-dilutive effect on earnings per
share.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;

</teva:EarningsPerShareTextBlock>
  <context id="eol_PE3710----096-K-0007_STD_p6m_20090630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE3710----096-K-0007_STD_p6m_20080630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE3710----096-K-0007_STD_p3m_20090630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
    </entity>
    <period>
      <startDate>2009-04-01</startDate>
      <endDate>2009-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE3710----096-K-0007_STD_p3m_20080630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
    </entity>
    <period>
      <startDate>2008-04-01</startDate>
      <endDate>2008-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE3710----096-K-0007_STD_Inst_20081231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="eol_PE3710----096-K-0007_STD_Inst_20071231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="eol_PE3710----096-K-0007_STD_Inst_20090630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
    </entity>
    <period>
      <instant>2009-06-30</instant>
    </period>
  </context>
  <context id="eol_PE3710----096-K-0007_STD_Inst_20080630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
    </entity>
    <period>
      <instant>2008-06-30</instant>
    </period>
  </context>
  <unit id="USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="Shares">
    <measure>shares</measure>
  </unit>
  <unit id="USDperShareItemType">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <xbrll:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <xbrll:loc xlink:href="#fnid_395221_2_11" xlink:label="fnid_395221_2_11" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_395221_2_9" xlink:label="fnid_395221_2_9" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_395221_4_11" xlink:label="fnid_395221_4_11" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_395221_4_13" xlink:label="fnid_395221_4_13" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_395221_4_16" xlink:label="fnid_395221_4_16" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_395221_4_9" xlink:label="fnid_395221_4_9" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_395222_2_4" xlink:label="fnid_395222_2_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_395222_2_9" xlink:label="fnid_395222_2_9" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_395223_2_12" xlink:label="fnid_395223_2_12" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_395223_2_26" xlink:label="fnid_395223_2_26" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_395223_2_34" xlink:label="fnid_395223_2_34" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_395223_2_35" xlink:label="fnid_395223_2_35" xlink:type="locator"/>
    <xbrll:footnote xlink:label="footnote_395206" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents an amount of less than $0.5 million.</xbrll:footnote>
    <xbrll:footnote xlink:label="footnote_395207" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">After giving retroactive effect to the adoption of Staff Position No. APB 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement), as further described in note 10(a).</xbrll:footnote>
    <xbrll:footnoteArc xlink:from="fnid_395221_2_11" xlink:to="footnote_395207" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_395221_2_9" xlink:to="footnote_395207" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_395221_4_11" xlink:to="footnote_395207" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_395221_4_13" xlink:to="footnote_395206" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_395221_4_16" xlink:to="footnote_395207" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_395221_4_9" xlink:to="footnote_395207" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_395222_2_4" xlink:to="footnote_395207" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_395222_2_9" xlink:to="footnote_395207" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_395223_2_12" xlink:to="footnote_395207" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_395223_2_26" xlink:to="footnote_395207" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_395223_2_34" xlink:to="footnote_395207" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_395223_2_35" xlink:to="footnote_395207" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
  </xbrll:footnoteLink>
</xbrl>